The antiarrhythmic and haemodynamic effects of three class III antiarrhythmic drugs, MS-551, sematilide and dofetilide, were examined in the coronary artery, ligation-reperfusion model of pentobarbitone-anaesthetized rats, a species deficient in functional cardiac IK. MS-551 is a non-selective potassium channel blocker, while both sematilide and dofetilide are selective delayed rectifier potassium (K) channel (IK) blockers. 2. Before coronary ligation, 3 and 10 mg kg-1 MS-551 decreased the heart rate by 6% (P < 0.01) and 12% (P < 0.01), and increased mean arterial pressure (MAP) by 14% (P < 0.05) and 33% (P < 0.01), respectively. Sematilide at 10 and 30 mg kg-1 also decreased the heart rate by 4% (P < 0.01) and 9% (P < 0.01), respectively, and the higher dose of 30 mg kg-1 decreased MAP by 29% (P < 0.01). Dofetilide, 1 mg kg-1, decreased the heart rate (P < 0.01), but had no significant effect on MAP. 3. The QT interval was increased by 10% (P < 0.01) and 31% (P < 0.01), when 3 and 10 mg kg-1 MS-551 were given. Sematilide and dofetilide had no effect on the QT interval. 4. Immediately after reperfusion, lethal ventricular fibrillation (VF) was induced in 80% of the saline group. MS-551 at 3 and 10 mg kg-1, reduced the incidence of lethal VF to 50% and 20% (P < 0.05). Neither dofetilide 1 mg kg-1 nor sematilide (10 and 30 mg kg-1) decreased the incidence of lethal VF (70%, 80% and 50%, respectively). None of the three drugs had any effect on the occurrence of reperfusion-induced VT or the total incidence of VF. However, 10 mg kg-1 MS-551 delayed the onset of reperfusion-induced VF (27 +/- 5 s compared with 12 +/- 2 s of the control group, P < 0.05). 5. In conclusion, in rats which are deficient in cardiac IK MS-551 prolonged the QT interval and reduced the incidence of sustained VF after reperfusion. Blockade of channels other than IK might participate in the defibrillatory effect of MS-551. Sematilide and dofetilide, which are selective IK blockers, did not increase the QT interval nor did they show antiarrhythmic effects Mechanisms other than K channel block may be involved in the different effects of the three drugs on blood pressure.
摘要
在戊巴比妥麻醉的大鼠冠状动脉结扎-再灌注模型中,研究了三种Ⅲ类抗心律失常药物MS-551、司美利特和多非利特的抗心律失常及血流动力学效应,该大鼠模型缺乏功能性心脏I K 通道。MS-551是一种非选择性钾通道阻滞剂,而司美利特和多非利特均为选择性延迟整流钾(K)通道(I K )阻滞剂。2. 在冠状动脉结扎前,3和10 mg·kg⁻¹的MS-551分别使心率降低6%(P<0.01)和12%(P<0.01),平均动脉压(MAP)分别升高14%(P<0.05)和33%(P<0.01)。10和30 mg·kg⁻¹的司美利特也分别使心率降低4%(P<0.01)和9%(P<0.01),30 mg·kg⁻¹的较高剂量使MAP降低29%(P<0.01)。1 mg·kg⁻¹的多非利特使心率降低(P<0.01),但对MAP无显著影响。3. 给予3和10 mg·kg⁻¹的MS-551时,QT间期分别延长10%(P<0.01)和31%(P<0.01)。司美利特和多非利特对QT间期无影响。4. 再灌注后即刻,80%的生理盐水组诱发了致死性室颤(VF)。3和10 mg·kg⁻¹的MS-551将致死性VF的发生率降至50%和20%(P<0.05)。1 mg·kg⁻¹的多非利特和司美利特(10和30 mg·kg⁻¹)均未降低致死性VF的发生率(分别为70%、80%和50%)。这三种药物对再灌注诱发的室性心动过速(VT)的发生或VF的总发生率均无影响。然而,10 mg·kg⁻¹的MS-551延迟了再灌注诱发的VF的发作(与对照组的12±2 s相比为27±5 s,P<0.05)。5. 总之,在缺乏心脏I K 通道的大鼠中,MS-551延长了QT间期并降低了再灌注后持续性VF的发生率。除I K 通道外的其他通道的阻断可能参与了MS-551的除颤作用。司美利特和多非利特作为选择性I K 阻滞剂,既未延长QT间期,也未显示出抗心律失常作用。钾通道阻断以外的机制可能参与了这三种药物对血压的不同影响。